Alseroxylon (Rautensin, Rauwiloid) is a norepinephrine reuptake inhibitor that has been investigated in the treatment of hypertension[1] and angina pectoris and as a sedative in psychoses.[2] It was at one time approved for use in the United States, but has since been discontinued.[3]
 Reserpine, the major component of alseroxylon | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII |
|
| ChEMBL | |
| Chemical and physical data | |
| Formula | Varies |
  (what is this?) (verify) | |
Alseroxylon is a purified fat-soluble extract of the root of Rauvolfia serpentina, containing reserpine and other nonadrenolytic amorphous alkaloids.[2]
References
edit- ^ Green RS, Davolos D (May 1956). "A long-term study of the effect of crude Rauwolfia serpentina and of its alseroxylon fraction in patients with hypertension". The American Journal of Medicine. 20 (5): 760–73. doi:10.1016/0002-9343(56)90158-9. PMID 13313574.
- ^ a b DrugBank DB00386
- ^ Approved Drug Products with Therapeutic Equivalence Evaluations (33rd ed.). 2013.
{{cite book}}:|work=ignored (help)